Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.

ABSTRACT:

Background and objective

The identification and quantification of potential drug-drug interactions is important for avoiding or minimizing the interaction-induced adverse events associated with specific drug combinations. Clinical studies in healthy subjects were performed to evaluate potential pharmacokinetic interactions between vortioxetine (Lu AA21004) and co-administered agents, including fluconazole (cytochrome P450 [CYP] 2C9, CYP2C19 and CYP3A inhibitor), ketoconazole (CYP3A and P-glycoprotein inhibitor), rifampicin (CYP inducer), bupropion (CYP2D6 inhibitor and CYP2B6 substrate), ethinyl estradiol/levonorgestrel (CYP3A substrates) and omeprazole (CYP2C19 substrate and inhibitor).

Methods

The ratio of central values of the test treatment to the reference treatment for

SUBMITTER: Chen G 

PROVIDER: S-EPMC3775155 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature